

# Theodore A Martinot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8277907/publications.pdf>

Version: 2024-02-01

17  
papers

570  
citations

840776

11  
h-index

839539

18  
g-index

22  
all docs

22  
docs citations

22  
times ranked

653  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6001-6016.	6.4	8
2	Carbamate and <i>N</i> -Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 389-396.	2.8	14
3	Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1435-1440.	2.8	7
4	Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1678-1688.	2.8	9
5	Development of a Zinc-Mediated Approach to a 2,3- <i>cis</i> -Pyrrolidine Arginase Inhibitor. <i>Organic Process Research and Development</i> , 2020, 24, 1457-1466.	2.7	6
6	Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 582-588.	2.8	18
7	Discovery of Amino-cyclobutane-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1530-1536.	2.8	38
8	Data-Rich Experimentation Enables Palladium-Catalyzed Couplings of Piperidines and Five-Membered (Hetero)aromatic Electrophiles. <i>Organic Process Research and Development</i> , 2019, 23, 1725-1739.	2.7	24
9	Process Safety Considerations for the Supply of a High-Energy Oxadiazole IDO1-Selective Inhibitor. <i>Organic Process Research and Development</i> , 2019, 23, 1178-1190.	2.7	4
10	A Design of Experiments Approach to a Robust Final Deprotection and Reactive Crystallization of IPI-926, A Novel Hedgehog Pathway Inhibitor. <i>Organic Process Research and Development</i> , 2015, 19, 1693-1702.	2.7	9
11	Development of a Manufacturing Process for an HCV Protease Inhibitor Candidate Molecule. <i>Organic Process Research and Development</i> , 2015, 19, 270-283.	2.7	12
12	Synthesis of the Bis-tetrahydropyran Core of Amphidinol 3. <i>Organic Letters</i> , 2010, 12, 3890-3893.	4.6	32
13	Artificial Genetic Systems: Exploiting the Aromaticity Formalism To Improve the Tautomeric Ratio for Isoguanosine Derivatives. <i>Journal of Organic Chemistry</i> , 2004, 69, 3972-3975.	3.2	42
14	Total Synthesis and Biological Evaluation of Amaryllidaceae Alkaloids: Narciclasine, ent-7-Deoxypancratistatin, Regioisomer of 7-Deoxypancratistatin, 10 $\beta$ -epi-Deoxypancratistatin, and Truncated Derivatives. <i>Journal of Organic Chemistry</i> , 2002, 67, 8726-8743.	3.2	182
15	Synthesis, Structure, and Biological Evaluation of Novel N- and O-Linked Diinositols. <i>Journal of the American Chemical Society</i> , 2002, 124, 10416-10426.	13.7	57
16	Novel O- and N-Linked Inositol Oligomers: A New Class of Unnatural Saccharide Mimics. <i>Synthesis</i> , 2001, 2001, 0952-0956.	2.3	22
17	A short chemoenzymatic synthesis of (+)-narciclasine. <i>Tetrahedron Letters</i> , 1999, 40, 3077-3080.	1.4	84